Measuring quality of life in patients with melanoma: Development of the FACT-Melanoma subscale

Journal of Supportive Oncology

Volumn 3, Issue 2, 2005, Pages 139-145

  Cormier, Janice N ^a,b   Davidson, Latunya ^a,b   Xing, Yan ^a,b   Webster, Kimberly ^a,b   Cella, David ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b Research and Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CANCER PATIENT; CANCER THERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; EMOTIONAL STABILITY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INTERVIEW; MALE; MEDICAL LITERATURE; MELANOMA; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RELIABILITY; REVIEW; SOCIAL INTERACTION; VALIDATION PROCESS; WELLBEING;

ADULT; AGED; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PILOT PROJECTS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 15944426057     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Cella DF, Tulsky DS. Quality of life in cancer: definition, purpose, and method of measurement. Cancer Invest 1993;11:327-336.
2. Langenhoff BS, Krabbe PF, Wobbes T, Ruers TJ. Quality of life as an outcome measure in surgical oncology. Br J Surg 2001;88:643-652.
3. Coates A, Gebski V, Signorini D, et al. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian NewZealand Breast Cancer Trials Group. J Clin Oncol 1992;10:1833-1838.
4. Coates A, Thomson D, McLeod GR, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 1993;29A:1731-1734.
5. Roychowdhury DF, Hayden A, Liepa AM. Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J Clin Oncol 2003;21:673-678.
6. Maisey NR, Norman A, Watson M, et al. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer 2002;38:1351-1357.
7. Jerkeman M, Kaasa S, Hjermstad M, Kvaloy S, Cavallin-Stahl E. Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Med Oncol 2001;18:85-94.
8. Sigurdardottir V, Bolund C, Sullivan M. Quality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapy. Acta Oncol 1996;35:149-158.
9. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 2003;1:79.
10. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997;15:974-986.
11. Ward WL, Hahn EA, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Qual Life Res 1999;8:181-195.
12. Weitzner MA, Meyers CA, Gelke CK, et al. The Functional Assessment of Cancer Therapy (FACT) scale: development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995;75:1151-1161.
13. List MA, D'Antonio LL, Cella DF, et al. The Performance Status Scale for head and neck cancer patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale: a study of utility and validity. Cancer 1996;77:2294-2301.
14. Cella DF, McCain NL, Peterman AH, Mo F, Wolen D. Development and validation of the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument. Qual Life Res 1996;5:450-463.
15. D'Antonio LL, Zimmerman GJ, Cella DF, Long SA. Quality of life and functional status measures in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 1996;122:482-487.
16. Esper P, Mo F, Chodak G, et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997;50:920-928.
17. Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D. Assessment ofquality of life in women undergoing hormonal therapy for breast cancer validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 1999;55:189-199.
18. Hinrichs CS, Gibbs JF, Driscoll D, et al.The effectiveness of complete decongestive physiotherapy for the treatment of lymphedema following groin dissection for melanoma. J Surg Oncol 2004;85:187-192.
19. Trask PC, Paterson AG, Hayasaka S, et al. Psychosocial characteristics of individuals with non-stage IV melanoma. J Clin Oncol 2001;19:2844-2850.
20. Doward LC, McKenna SP. Defining patient-reported outcomes. Value Health 2004;7(suppl 1): S4-S8.
21. Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess 1998;2: i-iv, 1-74.
22. Hallin P, Sullivan M, Kreuter M. Spinal cord injury and quality of life measures: a review of instrument psychometric quality. Spinal Cord 2000;38:509-523.
23. Cella DF, Tulsky DS, Gray G, et al.The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-579.
24. Berzon R, Hays RD, Shumaker SA.International use, application and performance of health-related quality of life instruments. Qual Life Res 1993;2:367-368.
25. Zubrod CG, Schneiderman M, Frei E. Appraisal of methods for the study of chemotherapy of cancer in man:comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis 1960;11:7-33.
26. Karnofsky DA, Burchenal JH. The Clinical Evaluation of Chemotherapeutic Agents in Cancer. New York, NY: Columbia University Press; 1949.
27. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-343.
28. Crowne D, Marlowe D. A new scale of social desirability independent of psychopathology. J Consult Psychol 1960;24:349-354.
29. Sigurdardottir V, Bolund C, Brandberg Y, Sullivan M. The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique. Qual Life Res 1993;2:193-203.
30. Cella DF, Jacobsen PB, Orav EJ, et al. A brief POMS measure of distress for cancer patients. J Chronic Dis 1987;40:939-942.
31. Cella D, Nowinski CJ. Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil 2002;83(suppl 2):S10-S17.
32. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. 6th ed. NewYork, NY: Springer; 2002.
33. Yellen SB, Cella DF, Webster K, Blenowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997;13:63-74.